Marco Sanduzzi‐Zamparelli

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors

Ignacio Melero, Maria de Miguel, Elena Garralda Cabanas, Guillermo de Velasco et autres

BACKGROUND: Resistance to anti-PD-1/PD-L1 therapy is a major unmet need. Growth Differentiation Factor 15 (GDF-15) has been identified as a key resistance factor for anti-PD-1/PD-L1 immunotherapy. Visugromab, a neutralizing anti-GDF-15 antibody, plus the anti-PD-1 antibody nivolumab (V+N) was evaluated in the first-in-human …

gb, es, ch, de, it, at (code pays fourni par la source)

Additional file 1 of Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors

Ignacio Melero, María de Miguel, Elena Garralda Cabanas, Guillermo de Velasco et autres

Additional file 1.

gb, es, ch, de, it, at (code pays fourni par la source)

Additional file 1 of Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors

Ignacio Melero, María de Miguel, Elena Garralda Cabanas, Guillermo de Velasco et autres

Additional file 1.

gb, es, ch, de, it, at (code pays fourni par la source)

Corrigendum to “Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes” [Eur J Cancer (May) (2025) 15:221:115404]

Marta Fortuny, Marta García-Calonge, Óscar Arrabal, Marco Sanduzzi‐Zamparelli et autres

es (code pays fourni par la source)

Erratum to ‘BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update’ [J Hepatol (2026) 631–654]

María Reig, Marco Sanduzzi‐Zamparelli, Alejandro Forner, Jordi Rimola et autres

es, us, de, it, ca (code pays fourni par la source)

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)

Marco Sanduzzi‐Zamparelli, Ana María Matilla, José Luis Lledó, Sergio Muñoz et autres

BACKGROUND & AIMS: Highly effective second-line treatments for hepatocellular carcinoma remain an unmet need. The GOING investigator-initiated Phase I/IIa trial evaluated regorafenib plus nivolumab (add-on) in patients who progressed on sorafenib (Cohort-A) or discontinued atezolizumab-bevacizumab (Cohort-B). METHODS: Patients received regorafenib for two …

es (code pays fourni par la source)

Correction: Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages

Carla Fuster-Anglada, Josep Maria Corominas, Aida Marsal, Neus Llarch et autres

The advent of immune checkpoint inhibition therapies has revolutionized cancer treatment over the past decade. These therapies utilize monoclonal antibodies targeting inhibitory checkpoints expressed by immune cells or their ligands expressed by tumor cells. By disrupting these receptor/ligand interactions, the functional inhibition …

es (code pays fourni par la source)

8 - MTDNA-STING ACTIVATION AS A STRATEGY TO ENHANCE CABOZANTINIB EFFICACY IN HEPATOCELLULAR CARCINOMA

Patricia Rider, Anna Tutusaus, Carlos Cuño-Gómiz, Flavia Sabino et autres

30 - MÁS ALLÁ DEL ALGORITMO: DETERMINANTES DE LA MIGRACIÓN DE TRATAMIENTO A TRAVÉS DE LOS ESTADIOS BCLC EN EL COMITÉ MULTIDISCIPLINAR (2020-2024)

Marta Fortuny, Diana Sánchez, Antonio De Rosa, Marco Sanduzzi‐Zamparelli et autres

Immune remodeling via mitochondria-dependent STING activation enhances cabozantinib response in hepatocellular carcinoma

Patricia Rider, Anna Tutusaus, Carlos Cuño-Gómiz, Flavia Savino et autres

BACKGROUND: Cabozantinib, a tyrosine kinase inhibitor (TKI) approved for advanced hepatocellular carcinoma (HCC), has established clinical benefit although the underlying immunomodulatory mechanisms, particularly those involving mitochondrial stress and the cGAS/STING pathway, remain poorly defined. METHODS: We assessed cabozantinib’s effects on mitochondrial integrity …

es (code pays fourni par la source)

Immune remodeling via mitochondria-dependent STING activation enhances cabozantinib response in hepatocellular carcinoma

Patricia Rider, Anna Tutusaus, Carlos Cuño-Gómiz, Flavia Savino et autres

Abstract Background Cabozantinib, a tyrosine kinase inhibitor (TKI) approved for advanced hepatocellular carcinoma (HCC), has established clinical benefit although the underlying immunomodulatory mechanisms, particularly those involving mitochondrial stress and the cGAS/STING pathway, remain poorly defined. Methods We assessed cabozantinib’s effects on mitochondrial …

es, us (code pays fourni par la source)

Immune remodeling via mitochondria-dependent STING activation enhances cabozantinib response in hepatocellular carcinoma

Patricia Rider, Anna Tutusaus, Carlos Cuño-Gómiz, Flavia Savino et autres

Abstract Background Cabozantinib, a tyrosine kinase inhibitor (TKI) approved for advanced hepatocellular carcinoma (HCC), has established clinical benefit although the underlying immunomodulatory mechanisms, particularly those involving mitochondrial stress and the cGAS/STING pathway, remain poorly defined. Methods We assessed cabozantinib’s effects on mitochondrial …

es, us (code pays fourni par la source)